Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart as Add-On Therapy to Efgartigimod in Generalized Myasthenia Gravis
NCT07284420Phase 2Recruiting
- Sponsor
- argenx
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of empasiprubart in myasthenia gravis (MG), sponsored by argenx. Started Dec 2025; status: recruiting.
02
Drugs
empasiprubart
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07284420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284420.